India is facing a shortage of Cisplatin and Carboplatin, two key chemotherapy drugs, due to rising platinum prices and supply disruptions linked to the West Asia crisis. This topic is important for aspirants preparing for GS2 Polity and Health-related issues through IAS coaching in Hyderabad and UPSC online coaching.
Platinum Drugs in Cancer Care
• Cisplatin and Carboplatin are platinum based chemotherapy agents widely used for treating oral, lung, cervical, ovarian, and breast cancers.
• Hospitals report difficulty in treating patients, with nearly 70% of cancer cases requiring these medicines.
• However, geopolitical tensions and raw material scarcity have triggered a crisis in availability.
Reasons for Shortage
• Platinum Price Surge: Prices rose from ₹2,700 per gram in 2023 to ₹7,800 per gram in 2026 due to supply chain disruptions.
• Hormuz Crisis: Conflict in West Asia disrupted shipping routes, affecting raw material imports.
• Supply Chain Bottlenecks: Limited global suppliers and dependence on imports worsened shortages.
• High Demand: India records 14–15 lakh new cancer cases annually, increasing reliance on these drugs.
Impact on India
• Patient Care: Oncologists report treatment delays and forced substitution with less effective drugs.
• Healthcare System Stress: Hospitals struggle to maintain stock, leading to rationing.
• Economic Burden: Rising drug costs increase out of pocket expenses for patients.
• Public Health Risk: Interruptions in chemotherapy cycles reduce survival chances.
Way Forward
• Develop indigenous production capacity for platinum based drugs under Make in India.
• Diversify import sources beyond West Asia to reduce dependency.
• Strengthen drug price regulation and ensure affordable access.
• Promote research in alternative therapies and biosimilars.
Conclusion
The chemotherapy drug crisis highlights India’s need for self reliant healthcare supply chains and resilient medical infrastructure. It also underlines the importance of reducing import dependence, strengthening domestic pharmaceutical manufacturing, and ensuring affordable cancer care for vulnerable patients.
